ATS reports Q3 adjusted EPS 32c, consensus 23c
Reports Q3 revenue $652.0M, consensus $651.21M. Reports Q3 Order Backlog $2.060B, 8.0% higher compared to $1.907B last year. “Today ATS ...
ATS sees Q4 revenue $650M-$710M, consensus $694.6M
The life sciences funnel remains strong, with a focus on strategic submarkets of pharmaceuticals, radiopharmaceuticals, and medical devices.